Searchable abstracts of presentations at key conferences in endocrinology

ea0077p89 | Neuroendocrinology and Pituitary | SFEBES2021

New presentation of asymptomatic acromegaly in patients with macroprolactinomas

de Bray Anne , Rahim Asad , Juszczak Agata

Background: Current guidance for the management of macroprolactinomas recommends full pituitary profile at baseline and subsequently only if symptomatic. Pituitary adenomas that co-secrete growth hormone and prolactin at presentation are well-recognised. Case reports of acromegaly after prolactinoma treatment are associated with symptomatic acromegaly. We present two patients with asymptomatic acromegaly years after diagnosis of macroprolactinoma.Patient...

ea0086p165 | Adrenal and Cardiovascular | SFEBES2022

Oral itraconazole augments iatrogenic Cushing’s syndrome and adrenal insufficiency after medication withdrawal

Maarouf Amro , Joseph Sonia , Juszczak Agata

A 37-year-old woman was referred to the endocrine team for the assessment of her adrenal axis, as she had been taking high dose prednisolone (20-40 mg) for several years for the management of her brittle asthma. Drug history included inhaled Symbicort 200/6 (SMART regime), tiotropium and montelukast. Her respiratory symptoms improved with the introduction of theophylline, thus enabling her prednisolone to be switched to oral hydrocortisone, with appropriate ’sick- day&#14...

ea0028p255 | Pituitary | SFEBES2012

Ipilimumab induced hypophysitis - an evolving clinical entity

Juszczak Agata , Karavitaki Niki , Grossman Ashley

Introduction: Ipilimumab (Yervoy, BMS) is a human monoclonal antibody increasingly used in oncology. It targets cytotoxic T lymphocytes antigen 4 (CTLA-4) promoting their proliferation and augmenting an anti-tumour response. It is licensed for the treatment of unresectable or metastatic melanoma and multiple clinical trials using this medication for other malignancies are ongoing. Ipilimumab related adverse reactions are mainly autoimmune and occur in 61% of patients, of which...

ea0032p232 | Clinical case reports – Pituitary/Adrenal | ECE2013

Bilateral third nerve palsy secondary to an apoplexy in a pituitary macroadenoma causing Cushing’s disease: a very rare complication of a rare entity

Juszczak Agata , Worth Claudia , Karavitaki Niki , Grossman Ashley B

Introduction: Bilateral 3rd nerve palsy is known in conditions such as diabetes mellitus, neurosarcoidosis, Guillain-Barre syndrome, multiple sclerosis, anterior or posterior communicating artery aneurysm or mesencephalic bleed/trauma. There are only single cases reported in association with pituitary adenoma or carcinoma, usually in the context of apoplexy. We describe a patient with Cushing’s disease and bilateral 3rd nerve palsy secondary to apoplexy in pituitary macro...

ea0074ncc12 | Highlighted Cases | SFENCC2021

A rare presentation of parathyroid carcinoma and brown tumours in a young woman with no associated genetic condition

de Bray Anne , Jones Sharon , Ahmad Ijaz , Juszczak Agata

Case history: A 34-year old Caucasian nurse presented to her GP with a 7 month history of abdominal pain. She was found to have PTH-dependent hypercalcaemia with Stage 3A chronic kidney disease (corrected calcium 3.43 mmol/l, phosphate 0.62 mmol/l, total vitamin D 32 nmol/l, PTH 214.9 pmol/l, creatinine 117 μmol/l and eGFR 45 ml/min/1.73m2). On direct questioning, she reported fatigue, generalised weakness and intermittent joint pains affecting her lower back and bo...

ea0094p38 | Bone and Calcium | SFEBES2023

Familial hypocalciuric hypercalcaemia - benign diagnosis not to be missed!

Linn Su Khin Kyaw , Hazlehurst Johnathan , Juszczak Agata

Background: Familial hypocalciuric hypercalcaemia (FHH) is a rare benign autosomal dominant condition which causes life-long mild to moderate hypercalcaemia. It is usually underdiagnosed due to lack of symptoms in majority of patients and low rate of screening even among endocrinologists. Recent NHS England National Genomic Directory testing criteria for FHH recommend testing patients presenting with hypercalcaemia and calcium creatinine clearance ratio (CCCR)...

ea0050p290 | Neuroendocrinology and Pituitary | SFEBES2017

An assessment of hypothalamus-pituitary-adrenal axis post-pituitary surgery: can day 8 morning cortisol predict normal SST?

Kounnis Valentinos , Juszczak Agata , Anguelova Lia , Cudlip Simon , Jafar-Mohammadi Bahram , Pal Aparna

Background: Short Synacthen test (SST) is commonly used for the assessment of the hypothalamus-pituitary-adrenal (HPA) axis after pituitary surgery. In our centre, patients are discharged on hydrocortisone on day 3 post-surgery and 9am cortisol on day 8 post-surgery is measured. Hydrocortisone is stopped if cortisol is ≥350 nmol/L on day 8. Six weeks post-surgery SST is performed and treatment adjusted. We aimed to assess the perfor...

ea0050p290 | Neuroendocrinology and Pituitary | SFEBES2017

An assessment of hypothalamus-pituitary-adrenal axis post-pituitary surgery: can day 8 morning cortisol predict normal SST?

Kounnis Valentinos , Juszczak Agata , Anguelova Lia , Cudlip Simon , Jafar-Mohammadi Bahram , Pal Aparna

Background: Short Synacthen test (SST) is commonly used for the assessment of the hypothalamus-pituitary-adrenal (HPA) axis after pituitary surgery. In our centre, patients are discharged on hydrocortisone on day 3 post-surgery and 9am cortisol on day 8 post-surgery is measured. Hydrocortisone is stopped if cortisol is ≥350 nmol/L on day 8. Six weeks post-surgery SST is performed and treatment adjusted. We aimed to assess the perfor...

ea0094p190 | Bone and Calcium | SFEBES2023

Parenteral bisphosphonate therapy is effective and safe when given prior to parathyroid surgery in severe primary hyperparathyroidism

Maarouf Amro , Winfield Jessica , Hazlehurst Jonathan , Joseph Sonia , Shepherd Lisa , Rahim Asad , Juszczak Agata

Background: Primary hyperparathyroidism may severely manifest with an adjusted calcium >3.5mmol/l and increased risk of prolonged postoperative hypocalcaemia. Formal consensus on preoperative optimisation appears lacking, especially around the utility of parenteral bisphosphonate treatment. Bisphosphonate therapy has been demonstrated to cause prolonged hypocalcaemia when given to patients with a history of parathyroidectomy....

ea0091wd6 | Workshop D: Disorders of the adrenal gland | SFEEU2023

Unusual Presentation of Adrenocortical Cancer

Linn Su Khin Kyaw , Juszczak Agata , Ronchi Cristina , Skordis Kassiani , Asia Miriam , Almond Max , Miller Ben , Myat Thaw Myat

Background : Adrenocortical cancer (ACC) is a very rare but aggressive tumour with annual incidence of 2 cases per million populations. Hypercalcaemia is a commonly encountered paraneoplastic manifestation of certain cancers such as lung, breast, kidney, gynaecological and neuroendocrine tumours but very rare in ACC. So far, there are only two cases of ACC and PTHrP-related hypercalcaemia reported in the literature.Case report: 32-year-old man presented ...